The future of clinical trials will be shaped by many factors, from evolving innovation to a stronger focus on patient-centricity. However the COVID-19 outbreak has driven the desire for more resilient clinical trials and accelerated the demand for decentralised trials and technology solutions to realise this transformation. Meanwhile, the deployment of remote clinical monitoring is proving its value in helping to keep trials going at a time when site management is particularly challenging.
But realising this transformation requires a flexible mindset, investment in new technologies and close collaboration between stakeholders.
Clinical trial management – speed, safety, cost, conduct and the move to remote study management – clinical monitoring and digital solutions
Trial design – innovation, AI powered data analytics
Regulatory framework – enabling change or barrier to progress?
Stakeholder engagement – patients, investigators regulators
- Are there challenges around a mass shift to remote study management and off-site monitoring?
- How are data collection, safety reporting and tracking processes evolving?
- What can be done to manage the risks and consequences of trials being suspended and re-started?
- How are clinical trial regulations and protocols evolving to accommodate new business processes and technology solutions?
- How will changes affect accessing patient populations?
- How can direct patient support services be improved?
- Dr Nuala Murphy, President, Clinical Research Services, ICON plc
- José Baselga, Executive Vice-President, Research & Development Oncology, AstraZeneca
- Christoph Koenen, Executive Vice President & Chief Medical Officer, Otsuka
- Dr Melanie Iversson, Chief Development Officer at Moderna
- Hannah Kuchler, FT Pharma and Biotech correspondent
Running order (EST subject to change)
10:45 Access opens
11:00 Opening remarks from FT chair
11:05 ICON Research update
11:20 Panel discussion